Drug intelligence / Profile preview

CYD10

Development stage: Unknown
Lead developer: Sanofi Pasteur
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

CYD10 is a clinical trial identifier for a study within the CYD series evaluating Sanofi Pasteur's Dengvaxia (CYD dengue vaccine), a live attenuated tetravalent dengue vaccine composed of chimeric yellow fever-dengue viruses (~5 log10 CCID50 of each DENV serotype). Developed as part of the pivotal efficacy trials (related to CYD14 and CYD15), it demonstrated efficacy against virologically confirmed dengue (59.2% combined) and severe dengue (79.1% after first dose) in children and adolescents, though long-term data showed risks in seronegative individuals. Administered subcutaneously in a 0/6/12-month schedule, it targets prevention of dengue fever in endemic regions but has conditional approvals due to safety concerns in non-immune populations.

Beyond the preview

Go deeper on CYD10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYD10.

Explore the full profile